Request SampleGlobal Varicella Attenuated Live Vaccine Sales Market Report 2023
SKU ID : QYR-22289675 | Publishing Date : 02-Jan-2023 | No. of pages : 117
Market Analysis and Insights: Global Varicella Attenuated Live Vaccine Market
A live attenuated varicella vaccine, derived from the Oka strain of VZV has clinical efficacy for the prevention of varicella.
Due to the COVID-19 pandemic, the global Varicella Attenuated Live Vaccine market size is estimated to be worth US$ 2553.6 million in 2022 and is forecast to a readjusted size of US$ 3440.8 million by 2029 with a CAGR of 4.3% during the forecast period 2023-2029. Fully considering the economic change by this health crisis, Monovalent Vaccine accounting for % of the Varicella Attenuated Live Vaccine global market in 2022, is projected to value US$ million by 2029, growing at a revised % CAGR from 2023 to 2029. While Kids Injection segment is altered to an % CAGR throughout this forecast period.
For the major players of Varicella Attenuated Live Vaccine, Merck maintained its first place in the ranking in 2019, followed by BCHT, Shanghai Institute, GSK and Keygen. Top 5 players accounted for about 95% of the Global Varicella Attenuated Live Vaccine revenue market share in 2019.
The sales market for Varicella Attenuated Live Vaccine was divided into five geographic regions. Asia-Pacific occupied the largest sales market share with about 58% in 2019. It is followed by North America and Europe with about 18% and about 13% respectively, while other regions have smaller market.
Global Varicella Attenuated Live Vaccine Scope and Market Size
The global Varicella Attenuated Live Vaccine market is segmented by company, region (country), type and application. Players, stakeholders, and other participants in the global Varicella Attenuated Live Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), type and application for the period 2018-2029.
Segment by Type
Monovalent Vaccine
Combination Vaccine
Segment by Application
Kids Injection
Adults Injection
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
By Company
Merck
BCHT
Shanghai Institute
GSK
Keygen
Green Cross
Biken
Shanghai Rongsheng Biotech
Changchun Changsheng Life Sciences Limited
A live attenuated varicella vaccine, derived from the Oka strain of VZV has clinical efficacy for the prevention of varicella.
Due to the COVID-19 pandemic, the global Varicella Attenuated Live Vaccine market size is estimated to be worth US$ 2553.6 million in 2022 and is forecast to a readjusted size of US$ 3440.8 million by 2029 with a CAGR of 4.3% during the forecast period 2023-2029. Fully considering the economic change by this health crisis, Monovalent Vaccine accounting for % of the Varicella Attenuated Live Vaccine global market in 2022, is projected to value US$ million by 2029, growing at a revised % CAGR from 2023 to 2029. While Kids Injection segment is altered to an % CAGR throughout this forecast period.
For the major players of Varicella Attenuated Live Vaccine, Merck maintained its first place in the ranking in 2019, followed by BCHT, Shanghai Institute, GSK and Keygen. Top 5 players accounted for about 95% of the Global Varicella Attenuated Live Vaccine revenue market share in 2019.
The sales market for Varicella Attenuated Live Vaccine was divided into five geographic regions. Asia-Pacific occupied the largest sales market share with about 58% in 2019. It is followed by North America and Europe with about 18% and about 13% respectively, while other regions have smaller market.
Global Varicella Attenuated Live Vaccine Scope and Market Size
The global Varicella Attenuated Live Vaccine market is segmented by company, region (country), type and application. Players, stakeholders, and other participants in the global Varicella Attenuated Live Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), type and application for the period 2018-2029.
Segment by Type
Monovalent Vaccine
Combination Vaccine
Segment by Application
Kids Injection
Adults Injection
By Region
United States
Europe
China
Japan
Southeast Asia
India
Other Regions
By Company
Merck
BCHT
Shanghai Institute
GSK
Keygen
Green Cross
Biken
Shanghai Rongsheng Biotech
Changchun Changsheng Life Sciences Limited
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
24/7 Research Support
Phone: +1 (888) 690-5999 
